TMEM150C and F2R as transcriptomic signatures for refractoriness to 7 + 3 induction therapy in acute myeloid leukemia
4 affiliations
- 1Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, Republic of Korea
- 2Department of Biochemistry, College of Medicine, Inje University, Busan, Republic of Korea
- 3Department of Biochemistry, College of Medicine, Dongguk University, Gyeongju, Republic of Korea
- 4Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Abstract
IntroductionAcute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with variable responses to standard 7 + 3 induction therapy. Although transcriptional profiling can capture biological phenotypes beyond genetic mutations, regimen-specific predictive biomarkers for 7 + 3 therapy have not been established due to methodological limitations in existing studies.MethodsTo identify transcriptomic signatures for 7 + 3 response, we analyzed two ethnically diverse AML cohorts: OHSU BeatAML2.0 (n = 264) and SIH/JIH/ZIH AML (n = 582). Machine learning algorithms, including least absolute shrinkage and selection operator (LASSO), and cross-cohort intersection analysis were employed to identify candidate genes associated with 7 + 3 therapy outcomes. The identified candidates were further evaluated using qRT-PCR in an independent AML patient cohort (n = 58) and cytarabine sensitivity assays in AML cell lines.ResultsIntersection analysis identified seven candidate genes showing concordant associations with refractory response in OHSU and poor overall survival in SIH/JIH/ZIH. In the independent clinical cohort, only 2 of the 7 candidates, TMEM150C and F2R, were reliably detectable, with significantly elevated expression in refractory patients (4.2-fold and 2.9-fold, respectively). AML cell lines with higher TMEM150C and F2R expression also exhibited reduced cytarabine sensitivity.DiscussionThese findings from ethnically diverse cohorts, independent patient validation, and functional studies suggest that TMEM150C and F2R may serve as potential predictive biomarkers for 7 + 3 therapy response in AML, enabling personalized treatment selection.
Related
- Systemic Mastocytosis With Associated Acute Myeloid Leukemia Identified After Induction Therapy: A Case Report and Literature Review
- The Utility of Computed Tomography of the Chest at the Time of Induction Chemotherapy in Patients with Acute Leukemia
- Response to Venetoclax and Azacitidine in Induction-Refractory Adult Acute Myeloid Leukemia with UBTF Tandem Duplication and Associated Aberrant Splicing: A Case Report
- Eltrombopag during induction chemotherapy in older patients with newly diagnosed acute myeloid leukemia is safe and reduces platelet transfusion requirements: The EPAG-2015 French Innovative Leukemia Organization phase 2 randomized trial.
- Induction of Mitochondrial Apoptosis and Suppression of Autophagic Pathways in T-Cell Acute Lymphoblastic Leukemia Cells by Natural Killer Cell–Derived Exosomes
BibTeX
@article{choi2026tmem150c,
title = {{TMEM150C and F2R as transcriptomic signatures for refractoriness to 7 + 3 induction therapy in acute myeloid leukemia}},
author = {Yu-Jeong Choi and Jiwoo Kim and Xuan Linh Mai and Arvie Camille V. de Guzman and Yong Jin An and Han Sun Kim and Han Sun Kim and Byung-Sik Cho and Sunghyouk Park},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1926332},
url = {https://doi.org/10.3389/fonc.2026.1926332},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - TMEM150C and F2R as transcriptomic signatures for refractoriness to 7 + 3 induction therapy in acute myeloid leukemia
AU - Yu-Jeong Choi
AU - Jiwoo Kim
AU - Xuan Linh Mai
AU - Arvie Camille V. de Guzman
AU - Yong Jin An
AU - Han Sun Kim
AU - Han Sun Kim
AU - Byung-Sik Cho
AU - Sunghyouk Park
PY - 2026
DA - 2026/10/23
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1926332
UR - https://doi.org/10.3389/fonc.2026.1926332
AB - IntroductionAcute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with variable responses to standard 7 + 3 induction therapy. Although transcriptional profiling can capture biological phenotypes beyond genetic mutations, regimen-specific predictive biomarkers for 7 + 3 therapy have not been established due to methodological limitations in existing studies.MethodsTo identify transcriptomic signatures for 7 + 3 response, we analyzed two ethnically diverse AML cohorts: OHSU BeatAML2.0 (n = 264) and SIH/JIH/ZIH AML (n = 582). Machine learning algorithms, including least absolute shrinkage and selection operator (LASSO), and cross-cohort intersection analysis were employed to identify candidate genes associated with 7 + 3 therapy outcomes. The identified candidates were further evaluated using qRT-PCR in an independent AML patient cohort (n = 58) and cytarabine sensitivity assays in AML cell lines.ResultsIntersection analysis identified seven candidate genes showing concordant associations with refractory response in OHSU and poor overall survival in SIH/JIH/ZIH. In the independent clinical cohort, only 2 of the 7 candidates, TMEM150C and F2R, were reliably detectable, with significantly elevated expression in refractory patients (4.2-fold and 2.9-fold, respectively). AML cell lines with higher TMEM150C and F2R expression also exhibited reduced cytarabine sensitivity.DiscussionThese findings from ethnically diverse cohorts, independent patient validation, and functional studies suggest that TMEM150C and F2R may serve as potential predictive biomarkers for 7 + 3 therapy response in AML, enabling personalized treatment selection.
SN - 2234-943X
ER -